Project Grant R01MH140376
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $781K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
- The National Institute of Mental Health awarded the University of Rochester $446,515 on September 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to develop and test LAFIYA Pharmacy, a multilevel intervention combining an evidence-based U.S. pharmacy HIV prevention delivery model with behavioral components designed to expand access to HIV testing and oral or long-acting injectable HIV prevention medication through community pharmacies in Ghana. The intervention targets men...
- The National Institute of Mental Health awarded Albert Einstein College of Medicine $462,000 on June 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to develop, formalize, and pilot an embedded status-neutral long-acting injectable (LAI) HIV antiretroviral implementation model in federally qualified health centers in the Bronx, New York. The study, titled "Planning for Implementation of Long-Acting Injectables in Status-Neutral HIV Primary Care" (R21MH142385),...
- The National Institute of Mental Health awarded the University of North Carolina at Chapel Hill $1,369,530 on September 23, 2025, under the Mental Health Research Grants program (CFDA 93.242) to evaluate field-based delivery of long-acting injectable antiretroviral therapy for persons with HIV who are out of care in North Carolina. The study, titled "RELAI" (Reaching Persons with HIV Who Are Out of Care Through Expedited Access to Long-Acting Injectable Antiretroviral Therapy),...
- The National Institute of Mental Health awarded the University of California, San Diego $441,215 on July 15, 2026, under the Mental Health Research Grants program (CFDA 93.242) to explore barriers and facilitators of HIV care and prevention service engagement among 18–45-year-old Black and Latinx sexual minority men in San Diego, San Bernardino, and Riverside Counties, California. The project investigates new intervention approaches to increase uptake and persistence of long-acting injectable...
- The National Institute of Mental Health awarded The Trustees of Columbia University in the City of New York $751,490 on April 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to develop and evaluate a comprehensive resource package designed to accelerate adoption of clinical decision support systems for long-acting injectable HIV prevention and treatment medications in U.S. HIV clinics. The project addresses implementation barriers to long-acting injectables (LAI) for...
- The National Institute of Mental Health awarded the University of Washington $729,551 on May 4, 2026, under the Mental Health Research Grants program (CFDA 93.242) to develop and evaluate pharmacy-based HIV pre-exposure prophylaxis (PrEP) services, training, and financial models. The project addresses barriers to PrEP access by expanding pharmacists' capacity to prescribe and dispense PrEP independently, overcoming clinic distance and stigma that limit treatment uptake and continuity. Three...
- The National Institute of Mental Health awarded the University of Alabama at Birmingham $678,550 on July 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to conduct a randomized clinical trial evaluating the Advanced HIV Re-engagement in Care (ARC) intervention in Zambia. ARC is a package of evidence-based, theory-informed elements delivered by supervised community health workers during hospitalization and the post-discharge period to improve outcomes for people with...
- The National Institute of Mental Health awarded The Johns Hopkins University $1.995 million on June 10, 2026, under the Mental Health Research Grants program (CFDA 93.242) to conduct a national study assessing the reach and public health impact of pharmacist-prescribed HIV pre-exposure prophylaxis (PrEP). The research evaluates where pharmacist-prescribed PrEP is occurring within states that permit it, which populations it reaches, and what population-level impacts it is having on HIV...
- The National Institute of Mental Health awarded the University of California, Los Angeles $787,498 under the Mental Health Research Grants program (CFDA 93.242) on July 1, 2026, to characterize HIV persistence and neuroinflammation in central nervous system (CNS) reservoirs in vivo using barcoded HIV tracking, spatial transcriptomics, single-cell RNA sequencing, and integration site analysis. The research investigates the contributions of T cell populations in HIV persistence and inflammation...
- The National Institute of Mental Health awarded the University of Alabama at Birmingham $1.809 million on June 5, 2026, under the Mental Health Research Grants program (CFDA 93.242) to develop novel preclinical models of neuroHIV that incorporate antiretroviral therapy suppression dynamics. The award funds development of next-generation neuroHIV models composed of autologous peripheral human immune cells, relevant human glial cell types, and an intact blood-brain barrier in the context of...